Navigation Links
PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA
Date:5/22/2009

ANNAPOLIS, Md., May 22 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that the Company has submitted its comprehensive regulatory strategy to the U.S. Food and Drug Administration (FDA) outlining the non-clinical and clinical development plans for licensure of SparVax(TM), a next generation recombinant protective antigen anthrax vaccine.

The FDA submission is in response to recent amendments issued by the Department of Health and Human Services (HHS) on April 15th and 22nd, 2009, to solicitation number RFP BARDA 08-15, outlining a requirement to develop and procure 25 million doses of a next generation rPA anthrax vaccine for the country's civilian biomedical stockpile.

In September 2008, PharmAthene received notification from HHS that its proposal for SparVax(TM) had been deemed technically acceptable and within the competitive range for procurement consideration. Since that time, PharmAthene has been engaged in negotiations with HHS under the proposals process.

David P. Wright, President and Chief Executive Officer of PharmAthene, noted, "We are pleased to have met our stated goal of submitting our regulatory plan to FDA by May 21st, well ahead of the June 15th submission deadline. We feel we have presented a comprehensive and credible path for the ultimate licensure of SparVax(TM). We continue to maintain an ongoing dialogue with FDA, and anticipate an expeditious review of our development plan. In the meantime, activities under the SparVax(TM) program continue to advance uninterrupted under a development contract for SparVax(TM) originally awarded by the National Institute of Allergy and Infectious Disease (NIAID) and transferred to the Biomedical Advanced Research and Deve
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program
2. PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
3. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
4. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
5. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
6. Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)
7. Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
8. D-Pharm Submits Investigational New Drug Application and Special Protocol Assessment to the FDA for Phase III Trial of DP-b99 in Acute Stroke Patients
9. AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product
10. U.S. Naval Medical Research Center Resubmits IND Application for Proposed RESUS Clinical Trial in Trauma Patients in the Out-of-Hospital Setting
11. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...irstCall/--Hologic,Inc.(HologicortheCompany)(Nasda...rofpremiumdiagnostics,medicalimagingsystemsandsurg...women,isusingtheannualmeetingoftheRadiologicalSoci...ovember29throughDecember3,2009tohighlightournewSec...workstationsoftware. ,, TheHologicSecurViewwork...
(Date:11/25/2009)...TrendsResearchGroup,Inc.releasedWave1ofits Launch...asesyndicatedmarketresearchprojecttrackingthelaunc...hthroughthefirstsixmonthsofavailability.Eachwaveof...ueDermatologistsandqualitativeinformationfromasubs...lestouse,typicalpatienttypes,productperceptions,pr...
(Date:11/25/2009)...swire/--AMPACFineChemicalsLLC(AFC),asubsidiaryofAm...daythatitreceivedtheEnvironmentalResponsibilityand...alSummit,sponsoredbytheCaliforniaManufacturersandT...talAssociation(IEA)andtheChemicalIndustryCouncilof...giousawardavailablefromallthreeorganizationsandgai...
Breaking Medicine Technology:New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 2New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 3Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2McGill JGH researchers successfully reverse multiple sclerosis in animals 9531 1McGill JGH researchers successfully reverse multiple sclerosis in animals 9531 2Partnership to Fight Chronic Disease Analyzes Key Provisions in Health Care Legislation Released To Date 54208 1Partnership to Fight Chronic Disease Analyzes Key Provisions in Health Care Legislation Released To Date 54208 2Hospira Launches Generic Oxaliplatin Injection 54204 1Hospira Launches Generic Oxaliplatin Injection 54204 2Hospira Launches Generic Oxaliplatin Injection 54204 3
..., June 3 Delcath Systems, Inc.,(Nasdaq: DCTH ) a...f,Bethlehem, PA, part of St. Luke,s Hospital & Hea...e III clinical trial for the treatment of,inoperab...any,s,Percutaneous Hepatic Perfusion (PHP) System ...ancer agent melphalan. This Phase III multi-center...
...boomers age drug-free treatments receive renewed a...D, FACS, FAAP to begin Plantar ...BioElectronics Corp.,(BIEL), the maker of the Acti...th an embedded battery operated microchip deliveri... to speed healing, today announced that,recent sal...
Other Medicine Technology:Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Luke's Cancer Center 2Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Luke's Cancer Center 3BioElectronics Announces Profitability Breakeven and Additional Clinical Trials 2BioElectronics Announces Profitability Breakeven and Additional Clinical Trials 3BioElectronics Announces Profitability Breakeven and Additional Clinical Trials 4BioElectronics Announces Profitability Breakeven and Additional Clinical Trials 5
(Date:11/25/2009)...fortuitous discovery that grew out of a collaborat...tentially offer hope to the nearly 10 million Amer... , Also known as hardening of the arteries, ...irculatory problem in which narrowed arteries redu...dered a red flag for vascular disease, heart attac...
(Date:11/25/2009)...mab, already used to fight rheumatoid arthritis, c..., , WEDNESDAY, Nov. 25 (HealthDay News) -...homa and rheumatoid arthritis now also shows some ...ype 1 diabetes. , The drug, rituximab (Rituxan)... insulin, even though the disease had destroyed so...
(Date:11/25/2009)...ors often plagued by neurological symptoms, study ... News) -- Neurological side effects are among the ... testicular cancer who were treated with cisplatin...he study included 1,409 Norwegian men treated for ... who took part in a follow-up survey conducted fro...
(Date:11/25/2009)..., ARLINGTON,Va.,Nov.25/PRNewswire-USNewswire/--The...ntHealthCareFraudActof2009,"S.2128,whichisdesigned...preventfraudinMedicare.ThebillwasintroducedbySen.G...severalprovisionstheAmericanAssociationforHomecare...AssociationproposedtoCongressinFebruary.Thoseprovi...
(Date:11/25/2009)...ug used to treat colorectal cancer also can revers... first-line therapy for the disease, researchers a... week. , Mntrier,s disease causes thickening of t...nd vomiting, as well as anemia and swelling in the... at increased risk for gastric cancer. Previously,...
Breaking Medicine News(10 mins):Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3Health News:American Association for Homecare Endorses New U.S. Senate Bill, the 'Prevent Health Care Fraud Act of 2009' 2Health News:Vanderbilt scientists report first effective medical therapy for rare stomach disorder 2
...f Alzheimer's disease can be identified by using t...luid, according to scientific research conducted b...onfusion can also be interpreted as early signs of...o known cure, but early detection and the administ...
... of AstraZeneca has been granted fast track design.... The drug also received the orphan drug designati...ary, follicular, locally advanced and metastatic m...urther. Medullary thyroid cancer accounts fo...
... a heart specialist at the National Institutes of ...fy smaller blood vessel // clogs. About 3 million ... not have the bulky clogs in main arteries. ...is very common among both men and women and causes...
...Ph.D associate professor within the Cardiovascular... Medical Center said that // small regulatory DN... The researchers scanned the vast human DNA co...ng the regulatory sequences and their control over...
...ges cost so dear, that cancer patients, ill afford...ng to the Charity Breast Cancer Care, 42% of breas...cancer cases, reported financial incapacity to aff... to the cost factor. Now, Breast cancer care is...
...ute of General Medical Sciences, one of the Nation..., five-year award of national Models of Infectious...vard Medical School and Harvard Pilgrim Health Car...used later to quickly detect and monitor infectiou...
Other Medicine News:Health News:Human Complexity Can Be Attributed To Regulatory Sequence 2Health News:Detecting Epidemics using statistics 2
...ce laboratory and a worldwide leader in innovative...an extensive test menu of highly complex and uniqu.... Owned by the University of Utah, ARUP Laboratori... university teaching hospitals and children's hosp...
...ce laboratory and a worldwide leader in innovative...an extensive test menu of highly complex and uniqu.... Owned by the University of Utah, ARUP Laboratori... university teaching hospitals and children's hosp...
...ce laboratory and a worldwide leader in innovative...an extensive test menu of highly complex and uniqu.... Owned by the University of Utah, ARUP Laboratori... university teaching hospitals and children's hosp...
...ce laboratory and a worldwide leader in innovative...an extensive test menu of highly complex and uniqu.... Owned by the University of Utah, ARUP Laboratori... university teaching hospitals and children's hosp...
Medicine Products: